Literature DB >> 8044828

Differential recovery of polymorphonuclear neutrophils, B and T cell subpopulations in the thymus, bone marrow, spleen and blood of mice following split-dose polychemotherapy.

J E Talmadge1, J D Jackson, C D Borgeson, G A Perry.   

Abstract

In these studies, we examined the effect of a maximum-tolerated, split-dose chemotherapy protocol of cyclophosphamide, cisplatin, and 1,3-bis(2-chloroethyl)-1-nitrosourea carmustine on neutrophil and lymphocyte, subpopulations in the peripheral blood (PBL), thymus, bone marrow and spleen. It was found that this protocol of polychemotherapy, modeled after the induction protocol used with autologous bone marrow transplantation for breast cancer, suppressed both B and T cell populations and T cell function at times when the absolute neutrophil count had returned to normal or supernormal numbers. In the peripheral blood, 7 days following initiation of chemotherapy, there was a twofold increase in the percentage of granulocytes as compared to the level in control animals on the basis of a differential count. The polymorphonuclear neutrophil (PMN) frequency in the bone marrow was increased on day 14 and statistically identical to that in control mice on all other days analyzed. In contrast to the bone marrow cells and PBL on day 7, the frequency of PMN in the spleen and thymus was depressed. B cells (B220+) were depressed in the pBL, spleen and bone marrow and took 18-32 days to return to their normal frequency, while the frequency of B cells in the thymus was increased owing to a loss of immature T cells. The percentage of CD3+ cells in the thymus, spleen and bone marrow was significantly increased and required 10-18 days to return to normal levels, while the absolute number of CD3+ cells in the blood varied around the normal value. The ratio of CD4+ to CD8+ cells in all the organs studied varied only slightly owing to a similar reconstitution of CD4+ and CD8+ cells. In contrast to the phenotypic recovery of the CD3+, CD4+, and CD8+ cells, the ability of the splenic lymphocytes to respond to concanavalin-A was depressed and remained depressed, despite the phenotypic reconstitution of the T cell subsets, on the basis of both percentage and absolute cell number. These results show a selective T and B cell depression following multi-drug, split-dose chemotherapy in tissue and blood leukocyte populations and a chronic depression in T cell function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8044828     DOI: 10.1007/bf01517182

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  40 in total

Review 1.  Dose intensification using combination alkylating agents and autologous bone marrow support in the treatment of primary and metastatic breast cancer: a review of the Duke Bone Marrow Transplantation Program experience.

Authors:  W P Peters
Journal:  Prog Clin Biol Res       Date:  1990

Review 2.  Reconstruction of the haemopoietic and immune systems after marrow transplantation.

Authors:  K Atkinson
Journal:  Bone Marrow Transplant       Date:  1990-04       Impact factor: 5.483

3.  Imbalances within the peripheral blood T-helper (CD4+) and T-suppressor (CD8+) cell populations in the reconstitution phase after human bone marrow transplantation.

Authors:  A Velardi; A Terenzi; S Cucciaioni; R Millo; C E Grossi; F Grignani; M F Martelli
Journal:  Blood       Date:  1988-05       Impact factor: 22.113

4.  Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity.

Authors:  M M Bortin; R L Truitt; A A Rimm; F H Bach
Journal:  Nature       Date:  1979-10-11       Impact factor: 49.962

5.  Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy.

Authors:  R P Witherspoon; K Kopecky; R F Storb; N Flournoy; K M Sullivan; R Sosa; H J Deeg; H D Ochs; M A Cheever; A Fefer; E D Thomas
Journal:  Transplantation       Date:  1982-02       Impact factor: 4.939

6.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

7.  Clonal analysis of T-cell deficiencies in autotransplant recipients.

Authors:  R A Miller; J Daley; R Ghalie; H Kaizer
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

8.  Return of immunohematopoietic impairment a long time after murine syngeneic bone marrow transplantation.

Authors:  T Skórski; M Kawalec; M Ratajczak; C Szczylik; J Kawiak
Journal:  Bone Marrow Transplant       Date:  1990-11       Impact factor: 5.483

9.  Thymus dictates major histocompatibility complex (MHC) specificity and immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC-restricted T cells.

Authors:  W M Kast; L P de Waal; C J Melief
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

10.  Phenotype of recovering lymphoid cell populations after marrow transplantation.

Authors:  K A Ault; J H Antin; D Ginsburg; S H Orkin; J M Rappeport; M L Keohan; P Martin; B R Smith
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.

Authors:  Justin L Wong; Scott E Evans
Journal:  Clin Chest Med       Date:  2017-03-01       Impact factor: 2.878

2.  Use of tumor lines with selectable markers in assessing the effect on experimental metastases of combination chemotherapy with alkylating agents.

Authors:  B E Miller; L Delmonico; K Vistisen; F R Miller
Journal:  Clin Exp Metastasis       Date:  1998-07       Impact factor: 5.150

3.  Modelling chemotherapy effects on granulopoiesis.

Authors:  Sibylle Schirm; Christoph Engel; Markus Loeffler; Markus Scholz
Journal:  BMC Syst Biol       Date:  2014-12-24

4.  A Dunnione Compound MB12662 Improves Cisplatin-Induced Tissue Injury and Emesis.

Authors:  Dongsun Park; In Geun Jo; Ja Young Jang; Tae Hwan Kwak; Sang Ku Yoo; Jeong Hee Jeon; Ehn-Kyoung Choi; Seong Soo Joo; Okjin Kim; Yun-Bae Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-09-01       Impact factor: 4.634

Review 5.  Isoxazole Derivatives as Regulators of Immune Functions.

Authors:  Michał Zimecki; Urszula Bąchor; Marcin Mączyński
Journal:  Molecules       Date:  2018-10-22       Impact factor: 4.411

6.  A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models.

Authors:  Jing Jin; Nina Xue; Yuan Liu; Rong Fu; Mingjin Wang; Ming Ji; Fangfang Lai; Jinping Hu; Xiaojian Wang; Qiong Xiao; Xiaoying Zhang; Dali Yin; Liping Bai; Xiaoguang Chen; Shuan Rao
Journal:  Acta Pharm Sin B       Date:  2019-11-14       Impact factor: 11.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.